ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

1.15
-0.005 (-0.43%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.005 -0.43% 1.15 1.02 1.255 1.27 1.27 1.27 733,994 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -2.92M -0.0070 -1.81 4.81M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.16p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 2.90p.

Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £4.81 million. Immupharma has a price to earnings ratio (PE ratio) of -1.81.

Immupharma Share Discussion Threads

Showing 38601 to 38624 of 39200 messages
Chat Pages: Latest  1556  1555  1554  1553  1552  1551  1550  1549  1548  1547  1546  1545  Older
DateSubjectAuthorDiscuss
25/8/2022
12:49
Whatever lies ahead for Lupuzor; IMM remains a most remunerative share to trade.
I have just bought 89k @ 5.794p and surely there is a 25% profit awaiting.

mudbath
25/8/2022
10:53
This was only found out after the trial, the smoking gun, patients with biomarkers benefit with drug and those without biomarkers dont..Of course u know this, right...
neo26
25/8/2022
10:16
NoddyThe patients were not chosen on the assumption of havin biomarkers.On third of the usa patients had biomarkers hence why the other two thirds in usa didnt benefit from drug.This new trial all patients will have biomarkers in this international phase.
neo26
25/8/2022
09:46
You can’t say the drug ‘worked’ on the subset with anti DNA antibodies! The study was not powered to show that endpoint so we it could well be a statistical anomaly. And as benanddaddy said it apparently didn’t work on the US patients with that bio marker which shows the vagaries of stats on small numbers
nobbygnome
25/8/2022
09:42
1 trading day left, fda approval on bank holiday.Tuesday gonna be fun..
neo26
25/8/2022
09:29
Avion are experienced, they have had 3 drugs approved by fda.The drug will be targeted on those with biomarkers, 60% of lupus patients have these biomarkers.
neo26
25/8/2022
07:12
The drug didn’t work on the anti-dsDNA US cohort and that has never been explained. And Avion are not a big pharma with experienced scientists. Have you read their website? They are a licensing, sales and marketing operation in different therapeutic areas.
bendaddy
24/8/2022
22:00
The drug works on those patients with biomarkers, avion will hav qualified scientist who will have gone over the data, they investing 25m to get it fda approved..
neo26
24/8/2022
19:42
But the drug won’t work IMHO so they will never receive any royalty payments…..
nobbygnome
24/8/2022
19:01
NoddyCurrent mkt cap is 20m, avion investing 25m to get drug through phase 3 and also into commercial production.Dont forget for usa imm have 17% royalty per annum and they have full rights for the rest of the world.I think next week will be interesting if phase 3 comes we go higher..
neo26
24/8/2022
10:51
Fanciful figures neo. There is no way the market cap will be 150-200 million during phase III due to the past history of the drug. Around £50 million is possible however IMHO
nobbygnome
24/8/2022
10:41
https://youtu.be/TAw39iaUYno
bloomberg2
24/8/2022
10:17
Once in phase 3 imm should have mkt cap over 50m.As is progresses phase 3 should be over 150m to 200m.Fully funded phase 3, lets see...
neo26
24/8/2022
10:00
The odds are very much in favour of getting FDA approval: PK study is done, met all its endpoints and satisfied the requirements. The FDA response is by way of a written response, type C which I understand is a further positive signal and usual at this stage. We then have a fully funded undervalued Phase 111 asset. Of course if the share price spikes there will be sellers, but once they are out of the way, we should see positive share price momentum as the company starts announcing patient recruitment etc.
1bond
24/8/2022
09:20
Master fund finance hey death spiral financiers
dillydally2
24/8/2022
09:15
SportbillyWell last year fda requested a pk study, the pk study was done earliar this year and passed with flying colors.Balls in fda court..
neo26
24/8/2022
09:00
Then sportbilly1976, "Houston, we have a problem!!
1bond
24/8/2022
08:53
Neo,

...and if FDA don't approve?

sportbilly1976
24/8/2022
08:37
For the record just bought a few more at 6.6…
nobbygnome
24/8/2022
08:11
The fda decision is whether trials can commence on phase 3.The fda required pk studies which avion completed successfully.Like i said previously if fda approves phase 3 the share price is double figures.
neo26
24/8/2022
08:09
Anyone spot Nobby(Ho hum)gnome ?
mudbath
24/8/2022
08:02
most will have (rightly) de-risked the day before the announcement
sportbilly1976
23/8/2022
14:38
Consolidating well.Can see this in double figure by tuesday..
neo26
23/8/2022
08:43
The irony is that most likely neo is doing exactly the same as me but he/she just doesn’t admit it. He will be out on any spike and move on to the next ramp. Ho hum…
nobbygnome
Chat Pages: Latest  1556  1555  1554  1553  1552  1551  1550  1549  1548  1547  1546  1545  Older